Answers are grounded in this paper and cite their sources.
One of the most important risk factors that determine the high incidence of both cardiovascular disease (CVD) and chronic kidney disease (CKD) is type 2 diabetes mellitus (T2DM). The search for therapeutic strategies capable of providing simultaneous cardio- and nephroprotection in patients with cardiovascular-kidney-metabolic (CKM) syndrome remains a critical unmet clinical need. Aim. To present a novel therapeutic strategy for cardiovascular-kidney-metabolic syndrome management and to evaluate the benefits of the highly selective nonsteroidal mineralocorticoid receptor antagonist (nsMRA) finerenone in reducing adverse cardiovascular and renal outcomes among patients with type 2 diabetes mellitus and chronic kidney disease, based on the results from large randomized clinical trials and the drug’s biochemical profile. To demonstrate that finerenone is currently the only nsMRA supported by robust evidence for significant cardio and nephroprotection in this patient population. Materials and methods. This review was conducted in accordance with the PRISMA 2020 (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. A systematic literature search was performed in electronic databases, including PubMed, Google Scholar, Scopus, Web of Science, and CrossRef using the following keywords: mineralocorticoid receptor antagonists, finerenone, type 2 diabetes mellitus, chronic kidney disease, and cardiovascular diseases, published during 2020–2025. An analytical review of the official recommendations of the American Heart Association was also performed, and the large representative NHANES III study was additionally examined. A total of 65 publications addressing the pathophysiology, clinical manifestations, and current approaches to the treatment of CKM syndrome were selected for discussion after screening the abstracts for relevance to these topics. Relevant studies were selected based on their focus on the investigation of molecular mechanisms of action, therapeutic efficacy, and the safety profile of finerenone compared with traditional antihypertensive agents. To achieve the stated objective, the following research methods were used: literature search, comparative analysis, generalization, and synthesis of scientific information. Results. In October 2023, the American Heart Association first formally defined CKM syndrome as a systemic disease characterized by pathophysiological interactions among metabolic risk factors, CKD, and the cardiovascular system, resulting in multiorgan dysfunction and elevated rates of adverse cardiovascular outcomes. This review details the role of mineralocorticoid receptors in CKM syndrome development, describes the mechanisms of effectiveness of mineralocorticoid receptor blockade in preventing progression of CKD, cardiovascular mortality, and the difference between nonsteroidal and steroidal MRAs. It also presents the results of randomized controlled trials confirming the cardio- and nephroprotective potential of finerenone. Conclusions. Today, finerenone, as a representative of nonsteroidal mineralocorticoid receptor antagonists with strong evidence of beneficial renal and cardiovascular effects in T2DM, should be used in patients with cardiovascular-kidney-metabolic syndrome alongside therapy with angiotensin-converting enzyme inhibitors / angiotensin II receptor blockers and sodium-glucose cotransporter-2 inhibitors for the purpose of cardio-renoprotection.
No takes yet. Share an insight, caveat, or question.
Ащеулова et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: